191 related articles for article (PubMed ID: 15090156)
1. Cytochrome p450 genotyping by multiplexed real-time dna sequencing with pyrosequencing technology.
Eriksson S; Berg LM; Wadelius M; Alderborn A
Assay Drug Dev Technol; 2002 Nov; 1(1 Pt 1):49-59. PubMed ID: 15090156
[TBL] [Abstract][Full Text] [Related]
2. Comparison of cytochrome P450 2C9 genotyping methods and implications for the clinical laboratory.
Aquilante CL; Lobmeyer MT; Langaee TY; Johnson JA
Pharmacotherapy; 2004 Jun; 24(6):720-6. PubMed ID: 15222661
[TBL] [Abstract][Full Text] [Related]
3. Introduction of the AmpliChip CYP450 Test to a South African cohort: a platform comparative prospective cohort study.
Dodgen TM; Hochfeld WE; Fickl H; Asfaha SM; Durandt C; Rheeder P; Drögemöller BI; Wright GE; Warnich L; Labuschagne CD; van Schalkwyk A; Gaedigk A; Pepper MS
BMC Med Genet; 2013 Jan; 14():20. PubMed ID: 23356658
[TBL] [Abstract][Full Text] [Related]
4. Clinical pharmacogenetics and potential application in personalized medicine.
Zhou SF; Di YM; Chan E; Du YM; Chow VD; Xue CC; Lai X; Wang JC; Li CG; Tian M; Duan W
Curr Drug Metab; 2008 Oct; 9(8):738-84. PubMed ID: 18855611
[TBL] [Abstract][Full Text] [Related]
5. Development of a PCR-based strategy for CYP2D6 genotyping including gene multiplication of worldwide potential use.
Dorado P; Cáceres MC; Pozo-Guisado E; Wong ML; Licinio J; Llerena A
Biotechniques; 2005 Oct; 39(4):571-4. PubMed ID: 16235570
[TBL] [Abstract][Full Text] [Related]
6. Clinical implications of pharmacogenetics of cytochrome P450 drug metabolizing enzymes.
Kirchheiner J; Seeringer A
Biochim Biophys Acta; 2007 Mar; 1770(3):489-94. PubMed ID: 17113714
[TBL] [Abstract][Full Text] [Related]
7. Polymorphic drug metabolizing CYP-enzymes--a pathogenic factor in oral lichen planus?
Kragelund C; Hansen C; Reibel J; Nauntofte B; Broesen K; Pedersen AM; Smidt D; Eiberg H; Torpet LA
J Oral Pathol Med; 2009 Jan; 38(1):63-71. PubMed ID: 19192051
[TBL] [Abstract][Full Text] [Related]
8. SNaPshot for pharmacogenetics by minisequencing.
Bender K
Methods Mol Biol; 2005; 297():243-52. PubMed ID: 15570112
[TBL] [Abstract][Full Text] [Related]
9. Genetic polymorphism of cytochrome P450 and methods for its determination.
Buzková H; Pechandová K; Slanar O; Perlík F
Prague Med Rep; 2006; 107(4):383-93. PubMed ID: 17402551
[TBL] [Abstract][Full Text] [Related]
10. Pharmacogenetic variation at CYP2C9, CYP2C19, and CYP2D6 at global and microgeographic scales.
Sistonen J; Fuselli S; Palo JU; Chauhan N; Padh H; Sajantila A
Pharmacogenet Genomics; 2009 Feb; 19(2):170-9. PubMed ID: 19151603
[TBL] [Abstract][Full Text] [Related]
11. Multiplex PCR-pyrosequencing assay for genotyping CYP3A5 polymorphisms.
Aquilante CL; Langaee TY; Anderson PL; Zineh I; Fletcher CV
Clin Chim Acta; 2006 Oct; 372(1-2):195-8. PubMed ID: 16701601
[TBL] [Abstract][Full Text] [Related]
12. Simultaneous genotyping of CYP2D6*3, *4, *5 and *6 polymorphisms in a Spanish population through multiplex long polymerase chain reaction and minisequencing multiplex single base extension analysis.
Crescenti A; Mas S; Gassó P; Baiget M; Bernardo M; Lafuente A
Clin Exp Pharmacol Physiol; 2007 Oct; 34(10):992-7. PubMed ID: 17714084
[TBL] [Abstract][Full Text] [Related]
13. CYP450 Genotype/Phenotype Concordance in Mexican Amerindian Indigenous Populations-Where to from Here for Global Precision Medicine?
de Andrés F; Sosa-Macías M; Ramos BPL; Naranjo MG; LLerena A
OMICS; 2017 Sep; 21(9):509-519. PubMed ID: 28873029
[TBL] [Abstract][Full Text] [Related]
14. Development of a single-tube PCR-pyrosequencing method for the simultaneous and rapid detection of four variant alleles of CYP2C9 gene polymorphism.
Okada Y; Nakamura K; Adachi A; Watai Y; Horiuchi R; Yamamoto K
J Clin Pharm Ther; 2008 Apr; 33(2):187-92. PubMed ID: 18315785
[TBL] [Abstract][Full Text] [Related]
15. AmpliChip CYP450 test: personalized medicine has arrived in psychiatry.
de Leon J
Expert Rev Mol Diagn; 2006 May; 6(3):277-86. PubMed ID: 16706732
[TBL] [Abstract][Full Text] [Related]
16. Candidate genetic modifiers of individual susceptibility to renal cell carcinoma: a study of polymorphic human xenobiotic-metabolizing enzymes.
Longuemaux S; Deloménie C; Gallou C; Méjean A; Vincent-Viry M; Bouvier R; Droz D; Krishnamoorthy R; Galteau MM; Junien C; Béroud C; Dupret JM
Cancer Res; 1999 Jun; 59(12):2903-8. PubMed ID: 10383153
[TBL] [Abstract][Full Text] [Related]
17. Rapid and comprehensive determination of cytochrome P450 CYP2D6 poor metabolizer genotypes by multiplex polymerase chain reaction.
Roberts R; Joyce P; Kennedy MA
Hum Mutat; 2000; 16(1):77-85. PubMed ID: 10874309
[TBL] [Abstract][Full Text] [Related]
18. Pharmacogenetic biomarkers as tools for improved drug therapy; emphasis on the cytochrome P450 system.
Ingelman-Sundberg M; Sim SC
Biochem Biophys Res Commun; 2010 May; 396(1):90-4. PubMed ID: 20494117
[TBL] [Abstract][Full Text] [Related]
19. Pyrosequencing-based screening for genetic polymorphisms in cytochrome P450 2B6 of potential clinical relevance.
Rohrbacher M; Kirchhof A; Geisslinger G; Lötsch J
Pharmacogenomics; 2006 Oct; 7(7):995-1002. PubMed ID: 17054410
[TBL] [Abstract][Full Text] [Related]
20. [A new, rapid and robust genotyping method for CYP2C9 and MDR1].
Verstuyft C; Morin S; Yang J; Loriot MA; Barbu V; Kerb R; Brinkmann U; Beaune P; Jaillon P; Becquemont L
Ann Biol Clin (Paris); 2003; 61(3):305-9. PubMed ID: 12805007
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
